Silence Therapeutics Continues Transformation, Improves US Visibility

Lists On NASDAQ, Starts Clinical Studies

 
• By John Davis
  
Generate a summary of this article
Listen to this article
Beta

The UK's Silence Therapeutics is moving its candidate products into early clinical studies in cardiovascular diseases and improving its visibility with a NASDAQ listing.

Tree
• Source: Shutterstock

Silence Therapeutics plc has capped a busy few months by listing its American Depositary Shares (ADSs) on the NASDAQ and by having an Investigational New Drug cleared by the US Food and Drug Administration for its lead cardiovascular short interfering ribonucleic acid (siRNA) therapeutic, SLN360. Human studies have also started with another product candidate, the potential thalassemia therapy, SLN124.

The UK AIM-listed and now NASDAQ-listed Silence has been transformed over the past 12 months, attracting big pharma collaborators that...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.